V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214516 | 20129922 | 1.7 | 0 | Curative (C) | 2016-12-24 | 2016-12-24 | EOX | Y | N | TRIAL | 101783151 |
| 20214519 | 20129923 | 1.7 | null | Neo-adjuvant (N) | 2021-01-30 | 2021-02-01 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100791381 |
| 20214521 | 20129924 | 0 | 60.6 | null | 2020-06-08 | 2020-06-15 | Trial Unspecified | 2 | null | TRIAL | 101029473 |
| 20214522 | 20129925 | 1.72 | 80.4 | Palliative (P) | 2019-03-30 | 2019-04-18 | Trial Unspecified | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 101274449 |
| 20214524 | 20129926 | 1.55 | 76.9 | null | 2018-06-06 | 2018-07-06 | Sorafenib | Y | null | SORAFENIB | 101170279 |
| 20214529 | 20129927 | 1.7 | 59.1 | Palliative (P) | 2016-08-28 | 2016-11-20 | CAPECITABINE + RT | 02 | N | CAPECITABINE + RT | 100024042 |
| 20214531 | 20129928 | 1.82 | 82.2 | Adjuvant (A) | 2017-11-14 | 2017-11-14 | CAPECITABINE + RT | 02 | N | CAPECITABINE + RT | 100381943 |
| 20214533 | 20129929 | 1.54 | 73.9 | Neo-adjuvant (N) | 2019-05-17 | 2019-05-17 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101072584 |
| 20214534 | 20129930 | 1.63 | 46 | Neo-adjuvant (N) | 2018-04-29 | 2019-03-03 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | CETUXIMAB + IRINOTECAN + MDG | 100653583 |
| 20214537 | 20129931 | 1.62 | 73 | Palliative (P) | 2018-02-08 | 2019-06-22 | EOX | 02 | Y | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100487088 |
| 20214538 | 20129932 | 1.64 | 75.9 | Neo-adjuvant (N) | 2016-03-12 | 2016-04-29 | Oxaliplatin + Raltitrexed | 2 | null | OXALIPLATIN + RALTITREXED | 100997126 |
| 20214539 | 20129933 | 1.7 | 86.4 | Not known (9) | 2018-06-01 | 2018-06-01 | Cetuximab + FLUOROURACIL + OXALIPLATIN | Y | Y | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100615855 |
| 20214540 | 20129934 | 1.69 | 62.9 | null | 2020-01-08 | 2020-01-08 | Sorafenib | 99 | null | SORAFENIB | 100605977 |
| 20214543 | 20129935 | 1.7 | 69.2 | Curative (C) | 2020-01-30 | 2020-02-12 | EOX | Y | Y | TRIAL | 100411732 |
| 20214545 | 20129936 | 1.78 | 72.4 | Palliative (P) | 2021-01-09 | 2021-01-10 | IRINOTECAN + MDG + PANITUMUMAB | 02 | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100908679 |
| 20214546 | 20129937 | 1.85 | 46.2 | Curative (C) | 2016-10-10 | 2016-10-31 | Sorafenib | 02 | Y | SORAFENIB | 100200134 |
| 20214548 | 20129938 | 0 | 62 | Neo-adjuvant (N) | 2017-08-29 | 2017-08-30 | Trial Unspecified | N | N | CETUXIMAB + IRINOTECAN + MDG | 100269889 |
| 20214551 | 20129939 | 1.84 | 96.8 | Neo-adjuvant (N) | null | 2020-05-20 | Sorafenib | 01 | N | SORAFENIB | 101676786 |
| 20214552 | 20129940 | 1.74 | 56 | Palliative (P) | 2020-11-25 | 2020-12-03 | EOX | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101170190 |
| 20214555 | 20129941 | 1.87 | 99 | Curative (C) | 2016-08-19 | 2016-08-26 | Cetuximab + Oxaliplatin + MdG Maint | N | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100661353 |
| 20214559 | 20129942 | 1.75 | 70.9 | null | 2019-01-06 | 2019-01-06 | CAPECITABINE + RT | 02 | null | CAPECITABINE + RT | 101653533 |
| 20214560 | 20129943 | 1.78 | 46 | null | 2019-12-06 | 2019-12-07 | Trial Unspecified | 1 | Y | TRIAL | 100455286 |
| 20214562 | 20129944 | 1.69 | 52.1 | Neo-adjuvant (N) | 2017-03-19 | 2018-06-12 | Sorafenib | 02 | Y | SORAFENIB | 101745583 |
| 20214564 | 20129945 | 1.71 | 109 | Neo-adjuvant (N) | 2016-12-22 | 2017-01-11 | Capecitabine 35days + RT | N | N | CAPECITABINE + RT | 101512155 |
| 20214565 | 20129946 | 1.72 | 62.95 | Adjuvant (A) | 2017-05-16 | 2017-06-04 | EOX | 02 | null | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101863214 |
| 20214566 | 20129947 | 1.62 | 100 | Neo-adjuvant (N) | 2018-08-14 | 2018-11-17 | Capecitabine 35days + RT | 02 | N | SORAFENIB | 101796512 |
| 20214567 | 20129948 | null | null | Neo-adjuvant (N) | 2021-06-09 | 2021-06-14 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 2 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101793255 |
| 20214568 | 20129949 | 1.43 | 88.3 | null | 2017-10-03 | 2017-11-04 | EOX | N | null | CETUXIMAB + IRINOTECAN + MDG | 101573049 |
| 20214570 | 20129950 | 1.69 | 68.1 | 03 | 2016-06-07 | 2016-06-11 | CAPECITABINE + RT | N | null | CAPECITABINE + RT | 100236251 |
| 20214573 | 20129951 | 1.84 | 79 | null | 2019-04-22 | 2019-05-12 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | null | CETUXIMAB + IRINOTECAN + MDG | 101335428 |
| 20214574 | 20129952 | null | null | null | 2018-12-10 | 2018-12-13 | Trial Unspecified | Y | null | TRIAL | 100412389 |
| 20214575 | 20129953 | 1.74 | 0 | Palliative (P) | 2019-04-16 | 2019-05-02 | Trial Unspecified | 1 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101812671 |
| 20214576 | 20129954 | 1.91 | 75.9 | Palliative (P) | 2015-07-10 | 2016-06-24 | EOX | 02 | N | SORAFENIB | 101854345 |
| 20214577 | 20129955 | 1.88 | 72.9 | Neo-adjuvant (N) | 2016-12-09 | 2016-12-10 | EOX | 02 | Y | SORAFENIB | 100095463 |
| 20214578 | 20129956 | 1.5 | 114.2 | Neo-adjuvant (N) | 2017-08-23 | 2018-06-20 | Cetuximab + Oxaliplatin + MdG Load | 02 | Y | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100931639 |
| 20214582 | 20129957 | 1.86 | 43.8 | null | 2021-07-17 | 2021-08-05 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 101265402 |
| 20214583 | 20129958 | null | 57.05 | null | 2016-09-05 | 2018-11-25 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | null | CAPECITABINE + RT | 101551641 |
| 20214584 | 20129959 | 1.79 | 64.5 | 03 | 2019-06-18 | 2019-07-02 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 100907580 |
| 20214585 | 20129960 | 2 | 76.5 | Palliative (P) | 2019-04-12 | 2019-04-12 | EOX | 01 | null | CETUXIMAB + IRINOTECAN + MDG | 100678103 |
| 20214586 | 20129961 | 1.63 | 87.6 | Palliative (P) | 2020-04-26 | 2020-05-18 | EOX | 01 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101070019 |
| 20214587 | 20129962 | 1.75 | 98.9 | Curative (C) | 2017-07-17 | 2017-07-29 | Cetuximab + Oxaliplatin + MdG Maint | Y | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101666972 |
| 20214601 | 20129963 | 1.76 | 113.2 | Adjuvant (A) | 2016-06-30 | 2016-09-01 | CAPECITABINE + RT | Y | N | CAPECITABINE + RT | 101834614 |
| 20214602 | 20129964 | 1.64 | 57.8 | Neo-adjuvant (N) | 2017-09-20 | 2017-10-05 | EOX | N | N | EOX | 100478831 |
| 20214607 | 20129965 | 1.81 | null | null | 2018-02-06 | 2018-03-12 | EOX | Y | null | TRIAL | 100330870 |
| 20214608 | 20129966 | 1.61 | null | Palliative (P) | 2020-07-24 | 2020-07-25 | EOX | 01 | null | OXALIPLATIN + RALTITREXED | 100501329 |
| 20214612 | 20129967 | 1.62 | 61.2 | Neo-adjuvant (N) | 2021-08-08 | 2021-12-10 | EOX | 2 | Y | OXALIPLATIN + RALTITREXED | 100825920 |
| 20214613 | 20129968 | 1.81 | 86.4 | Neo-adjuvant (N) | 2013-05-20 | 2017-07-04 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100052392 |
| 20214614 | 20129969 | 1.6 | 82.3 | Neo-adjuvant (N) | 2016-12-09 | 2016-12-20 | Capecitabine 35days + RT | null | N | CAPECITABINE + RT | 101576131 |
| 20214616 | 20129970 | 1.75 | 68.4 | null | 2017-11-23 | 2017-12-07 | Trial Unspecified | N | null | TRIAL | 101001753 |
| 20214618 | 20129971 | 1.87 | 74.3 | Curative (C) | 2020-08-08 | 2020-08-24 | EOX | 02 | null | SORAFENIB | 100542583 |